Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD

Jason R. Stubbs, Arun Idiculla, Joyce Slusser, Rochelle Menard, Leigh Quarles

Research output: Contribution to journalArticle

134 Citations (Scopus)

Abstract

In vitro, monocyte 1α-hydroxylase converts 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D to regulate local innate immune responses, but whether 25(OH)D repletion affects vitamin D-responsive monocyte pathways in vivo is unknown. Here, we identified seven patients who had 25(OH)D insufficiency and were undergoing long-term hemodialysis and assessed changes after cholecalciferol and paricalcitol therapies in both vitamin D-responsive proteins in circulating monocytes and serum levels of inflammatory cytokines. Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1α-hydroxylase levels. The CD16+ " inflammatory" monocyte subset responded to 25(OH)D repletion the most, demonstrating the greatest increase in vitamin D receptor expression after cholecalciferol. Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. These data suggest that nutritional vitamin D therapy has a biologic effect on circulating monocytes and associated inflammatory markers in patients with ESRD.

Original languageEnglish (US)
Pages (from-to)353-361
Number of pages9
JournalJournal of the American Society of Nephrology
Volume21
Issue number2
DOIs
StatePublished - Feb 1 2010

Fingerprint

Calcitriol
Cholecalciferol
Chronic Kidney Failure
Monocytes
Cytokines
Mixed Function Oxygenases
Vitamin D
Proteins
Calcitriol Receptors
Therapeutics
Serum
Interleukin-8
Innate Immunity
Renal Dialysis
Interleukin-6

All Science Journal Classification (ASJC) codes

  • Medicine(all)
  • Nephrology

Cite this

Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD. / Stubbs, Jason R.; Idiculla, Arun; Slusser, Joyce; Menard, Rochelle; Quarles, Leigh.

In: Journal of the American Society of Nephrology, Vol. 21, No. 2, 01.02.2010, p. 353-361.

Research output: Contribution to journalArticle

@article{5af647274b7849c3a6e02cc13953cdf2,
title = "Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD",
abstract = "In vitro, monocyte 1α-hydroxylase converts 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D to regulate local innate immune responses, but whether 25(OH)D repletion affects vitamin D-responsive monocyte pathways in vivo is unknown. Here, we identified seven patients who had 25(OH)D insufficiency and were undergoing long-term hemodialysis and assessed changes after cholecalciferol and paricalcitol therapies in both vitamin D-responsive proteins in circulating monocytes and serum levels of inflammatory cytokines. Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1α-hydroxylase levels. The CD16+ {"} inflammatory{"} monocyte subset responded to 25(OH)D repletion the most, demonstrating the greatest increase in vitamin D receptor expression after cholecalciferol. Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. These data suggest that nutritional vitamin D therapy has a biologic effect on circulating monocytes and associated inflammatory markers in patients with ESRD.",
author = "Stubbs, {Jason R.} and Arun Idiculla and Joyce Slusser and Rochelle Menard and Leigh Quarles",
year = "2010",
month = "2",
day = "1",
doi = "10.1681/ASN.2009040451",
language = "English (US)",
volume = "21",
pages = "353--361",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "2",

}

TY - JOUR

T1 - Cholecalciferol supplementation alters calcitriol-responsive monocyte proteins and decreases inflammatory cytokines in ESRD

AU - Stubbs, Jason R.

AU - Idiculla, Arun

AU - Slusser, Joyce

AU - Menard, Rochelle

AU - Quarles, Leigh

PY - 2010/2/1

Y1 - 2010/2/1

N2 - In vitro, monocyte 1α-hydroxylase converts 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D to regulate local innate immune responses, but whether 25(OH)D repletion affects vitamin D-responsive monocyte pathways in vivo is unknown. Here, we identified seven patients who had 25(OH)D insufficiency and were undergoing long-term hemodialysis and assessed changes after cholecalciferol and paricalcitol therapies in both vitamin D-responsive proteins in circulating monocytes and serum levels of inflammatory cytokines. Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1α-hydroxylase levels. The CD16+ " inflammatory" monocyte subset responded to 25(OH)D repletion the most, demonstrating the greatest increase in vitamin D receptor expression after cholecalciferol. Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. These data suggest that nutritional vitamin D therapy has a biologic effect on circulating monocytes and associated inflammatory markers in patients with ESRD.

AB - In vitro, monocyte 1α-hydroxylase converts 25-hydroxyvitamin D [25(OH)D] to 1,25-dihydroxyvitamin D to regulate local innate immune responses, but whether 25(OH)D repletion affects vitamin D-responsive monocyte pathways in vivo is unknown. Here, we identified seven patients who had 25(OH)D insufficiency and were undergoing long-term hemodialysis and assessed changes after cholecalciferol and paricalcitol therapies in both vitamin D-responsive proteins in circulating monocytes and serum levels of inflammatory cytokines. Cholecalciferol therapy increased serum 25(OH)D levels four-fold, monocyte vitamin D receptor expression three-fold, and 24-hydroxylase expression; therapy decreased monocyte 1α-hydroxylase levels. The CD16+ " inflammatory" monocyte subset responded to 25(OH)D repletion the most, demonstrating the greatest increase in vitamin D receptor expression after cholecalciferol. Cholecalciferol therapy reduced circulating levels of inflammatory cytokines, including IL-8, IL-6, and TNF. These data suggest that nutritional vitamin D therapy has a biologic effect on circulating monocytes and associated inflammatory markers in patients with ESRD.

UR - http://www.scopus.com/inward/record.url?scp=77949378067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949378067&partnerID=8YFLogxK

U2 - 10.1681/ASN.2009040451

DO - 10.1681/ASN.2009040451

M3 - Article

VL - 21

SP - 353

EP - 361

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 2

ER -